RESEARCH PAPER

The cannabinoid CB₂ receptor agonist AM1241 enhances neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis

Hava Karsenty Avraham¹, Shuxian Jiang¹, Yigong Fu¹, Edward Rockenstein², Alexandros Makriyannis³, Alexander Zvonok³, Eliezer Masliah² and Shalom Avraham¹

¹Division of Experimental Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA, ²Department of Neurosciences and Pathology, University of California, San Diego, School of Medicine, La Jolla, CA, USA, and ³Center for Drug Discovery, Northeastern University, Boston, MA, USA

Correspondence

Shalom Avraham, Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Research North, 99 Brookline Avenue, 3rd Floor, Boston, MA 02215, USA. E-mail: havraham2007@gmail.com

Keywords

CB₂ agonist; neural progenitor cells; HIV-1 Gp120 protein; GFAP/Gp120 transgenic mice; neurogenesis

Received

14 May 2013

Revised

12 September 2013

Accepted

3 October 2013

BACKGROUND AND PURPOSE

HIV-1 glycoprotein Gp120 induces apoptosis in rodent and human neurons *in vitro* and *in vivo*. HIV-1/Gp120 is involved in the pathogenesis of HIV-associated dementia (HAD) and inhibits proliferation of adult neural progenitor cells (NPCs) in glial fibrillary acidic protein (GFAP)/Gp120 transgenic (Tg) mice. As cannabinoids exert neuroprotective effects in several model systems, we examined the protective effects of the CB₂ receptor agonist AM1241 on Gp120-mediated insults on neurogenesis.

EXPERIMENTAL APPROACH

We assessed the effects of AM1241 on survival and apoptosis in cultures of human and murine NPCs with immunohistochemical and TUNEL techniques. Neurogenesis in the hippocampus of GFAP/Gp120 transgenic mice *in vivo* was also assessed by immunohistochemistry.

KEY RESULTS

AM1241 inhibited *in vitro* Gp120-mediated neurotoxicity and apoptosis of primary human and murine NPCs and increased their survival. AM1241 also promoted differentiation of NPCs to neuronal cells. While GFAP/Gp120 Tg mice exhibited impaired neurogenesis, as indicated by reduction in BrdU⁺ cells and doublecortin⁺ (DCX⁺) cells, and a decrease in cells with proliferating cell nuclear antigen (PCNA), administration of AM1241 to GFAP/Gp120 Tg mice resulted in enhanced *in vivo* neurogenesis in the hippocampus as indicated by increase in neuroblasts, neuronal cells, BrdU⁺ cells and PCNA⁺ cells. Astrogliosis and gliogenesis were decreased in GFAP/Gp120 Tg mice treated with AM1241, compared with those treated with vehicle.

CONCLUSIONS AND IMPLICATIONS

The CB₂ receptor agonist rescued impaired neurogenesis caused by HIV-1/Gp120 insult. Thus, CB₂ receptor agonists may act as neuroprotective agents, restoring impaired neurogenesis in patients with HAD.

Abbreviations

ACEA, arachidonyl-2'-chloroethylamide; AEA, anandamide; BrdU, bromodeoxyuridine; CB₁, cannabinoid receptor type 1; CB₂, cannabinoid receptor type 2; DAGL, diacylglycerol lipase; DCX⁺, doublecortin; EB, embryoid body; ES, embryonic stem cells; FAAH, fatty acid amide hydrolase; GFAP, glial fibrillary acidic protein; HAART, highly active antiretroviral therapy; HAD, HIV-associated dementia; HAND, HIV-associated neurocognitive disorder; NPC, neural progenitor cell; PCNA, proliferating cell nuclear antigen; SGZ, subgranular zone; SVZ, subventricular zone; Tg, transgenic

Introduction

Neurological impairment affects approximately 40% of HIV-infected patients. HIV-1 virus enters the CNS at the early phase of infection and induces motor and cognitive dysfunction and behavioural changes (Wiley *et al.*, 1999; Shah and Kumar, 2010). Despite the use of highly active antiretroviral therapy (HAART), the prevalence of HIV-associated neurocognitive disorder (HAND) is increasing and remains a significant risk factor for AIDS mortality (Cherner *et al.*, 2004; Price and Spudich, 2008). The HIV-1 envelope protein Gp120 is a mediator of HAND (Mattson *et al.*, 2005; McArthur *et al.*, 2010; Scott *et al.*, 2011) and decreases adult hippocampal neural precursor cell proliferation. Gp120 immunoreactivity has been demonstrated throughout the brain, including the hippocampus, in individuals infected with HIV-1 (Mattson *et al.*, 2005; Scott *et al.*, 2011). Gp120 is a potent neurotoxin that triggers inflammatory response by increasing production and secretion of proinflammatory cytokines such as TNF- α , IL-1 β and IL-6 in HIV-1 encephalitis (Fauci, 1988; Shah and Kumar, 2010; Louboutin and Strayer, 2012). Gp120 also increases the number of activated microglia in the brain (Albright *et al.*, 2001).

The glial fibrillary acidic protein (GFAP)/Gp120 transgenic (Tg) mouse model reproduces some of the neurological, learning and memory deficits seen in patients with HIV-1 (Toggas *et al.*, 1994; 1996; Mucke *et al.*, 1995; Krucker *et al.*, 1998). Astroglia appears around 5–6 months and degeneration of neurons appears at 7–9 months in brains of these mice (Toggas *et al.*, 1994; 1996; Mucke *et al.*, 1995). These mice display deficits in neurogenesis in the hippocampus where adult neural progenitor cells (NPCs) have decreased proliferation via checkpoint kinase-mediated cell-cycle withdrawal and G₁ arrest (Okamoto *et al.*, 2007). The severity of damage in brains of GFAP/Gp120 Tg mice is correlated positively with the level of Gp120 expression in various brain regions (Toggas *et al.*, 1994).

The endogenous cannabinoid (endocannabinoid) system, an important lipid signalling system in modulating physiological responses in CNS and immune system, plays a role in modulating neurotoxic and inflammatory processes in the brain and exhibits neuroprotective properties (Ramírez *et al.*, 2005; Sarne and Mechoulam, 2005). This system comprises the endogenous ligands (endocannabinoids) chiefly anandamide (AEA) and 2-arachidonylglycerol, agonists at the cannabinoid receptor type 1 (CB₁) and cannabinoid receptor type 2 (CB₂) receptors respectively (receptor nomenclature follows Alexander *et al.*, 2013).

In vivo, cannabinoids decrease hippocampal neuronal loss and infarct volume after cerebral ischaemia (Nagayama *et al.*, 1999), acute brain trauma (Panikashvili *et al.*, 2006) and

ouabain-induced excitotoxicity (van der Stelt *et al.*, 2001). Recently, it has been reported that activation of CB₂ receptors promoted NPC proliferation via mTORC1 signalling, and inhibited HIV-1/Gp120-induced synapse loss between hippocampal neurons (Kim *et al.*, 2011).

Here we have examined whether selective agonists of the CB₂ receptor exerted neuroprotective effects on Gp120-mediated insults on NPCs *in vitro* and *in vivo*. We found that, *in vitro*, the CB₂ receptor agonist AM1241 inhibited HIV-1/Gp120-mediated apoptosis and enhanced the survival of both human and murine NPCs as well as their differentiation to neuronal cells. Further, administration of AM1241 to GFAP/Gp120 Tg mice *in vivo* enhanced neurogenesis in the hippocampus.

Methods

Culture of murine embryonic stem (ES) cells and their differentiation to NPCs

NeuroCult proliferation medium was prepared with 1:9 ratio of NeuroCult Proliferation Supplements (#05701; StemCell Technologies Vancouver, Canada) to NeuroCult basal Medium (StemCell Technology #05700), supplemented with 20 ng·mL⁻¹ of rhEGF (StemCell Technology #02633), 20 ng·mL⁻¹ of rhFGF-b (StemCell Technology #02634), 20 ng·mL⁻¹ of rmLIF (StemCell Technology #02740).

Formation of embryoid bodies (EBs) from murine ES cells was carried out using established protocols (www.lifetechnologies.com). Murine ES cells, E14/GFP cells, were obtained commercially from StemCell Technologies and were cultured following the protocol provided by StemCell Technologies. At day 4 of culture, EBs were harvested and placed into sterile polypropylene tubes. EBs were allowed to settle for about 5 min, the supernatant were aspirated and NeuroCult Proliferation medium was added. About 30 EBs per well or about 300 EBs per plate were seeded, supplemented with 100 nM of cannabinoid agonist. The cell cultures were incubated at 37°C with 5% CO₂ for 10 to 12 days, in a medium that was changed every 3 days. Cells were analysed by immunostaining, RT-PCR and Western blot as indicated.

Primary human and murine neural progenitor cells

We used primary normal human NPCs (hNPCs), from Chemicon (Catalogue Number SCC007; Upstate Chemicon, Billerica, MA). The hNPCs were characterized regularly by the human neural stem cell characterization kit (Catalogue Number SCR060; EMD Millipore, Billerica, MA), which contained the molecular markers Nestin, Sox 2 and Musashi.

These cells were maintained and cultured using the manufacturer's protocol (Chemicon, Inc.). In addition, we employed primary normal murine NPCs (mNPCs), commercially available from Chemicon, which were characterized by molecular markers for neural stem cells based on the manufacturer's protocol.

CB₁ and CB₂ receptor expression in human NPCs

RNA from human NPC was extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. cDNA and PCR amplification were performed with the TITANIUM One-Step RT-PCR Kit (BD Biosciences, San Jose, CA). CB₁ was amplified using primers: 5'-CGT GGG CAG CCT GTT CCT CA-3' and 5'-CAT GCG GGC TTG GTC TGG-3', which yielded a product of 403 bp. CB₂ was amplified using: 5'-CCA TGG AGG AAT GCT GGG TG-3' and 5'-TCA GCA ATC AGA GAG GTC TAG-3', which yielded a product of 1100 bp. GAPDH was used as a positive control with primers: 5'-CTC ACT GGC ATG GCC TTC CG-3' and 5'-ACC ACC CTG TTG CTG TAG CC-3', which yielded a product of 292 bp.

Western blots were used to analysis CB₁ and CB₂ receptor expression. NPCs were lysed in RIPA lysis buffer and the samples were separated by SDS-PAGE. The antibodies for human CB₁ and CB₂ receptors were from Cayman. SH-SY5Y human neuroblastoma cells were used as a negative control for CB₂ receptor expression and as a positive control for CB₁ receptors.

RT-PCR analysis of CB₁ and CB₂ receptor expression

RNA from total mES cells was extracted using the RNeasy Mini Kit (Qiagen) following the manufacturer's protocol. A QIAshredder spin column and DNase digestion were included in the isolation procedure to limit the possibility of PCR amplification of CB₁ and CB₂ receptors from genomic DNA. cDNA and PCR amplification were performed with the TITANIUM One-Step RT-PCR Kit using 200 ng of RNA as a template for first-strand synthesis. CB₁ was amplified using primers: 5'-CGT GGG CAG CCT GTT CCT CA-3' and 5'-CAT GCG GGC TTG GTC TGG-3', which yielded a product of 403 bp. CB₂ was amplified using: 5'-CCG GAA AAG AGG ATG GCA ATG AAT-3' and 5'-CTG CTG AGC GCC CTG GAG AAC-3', which yielded a product of 479 bp. GAPDH was used as a positive internal control with primers: 5'-CTC ACT GGC ATG GCC TTC CG-3' and 5'-ACC ACC CTG TTG CTG TAG CC-3', which yielded a product of 292 bp. The template was first denatured at 94°C for 2 min followed by 35 cycles (94°C for 30 sec, 58°C for 30 sec and 68°C for 1 min), then by 68°C for 2 min in a myCycler Personal Thermal Cycler (Bio-Rad Laboratories, Inc). Aliquots (20 µL) of the PCR products were run on a 1.2% agarose gel containing 0.5 mg/mL ethidium bromide.

Animals

All animal care and experimental protocols complied with the guidelines from the National Institutes of Health and the Association for Assessment and Accreditation of Laboratory Animal Care and were approved by the Institutional Animal

Care & Use Committee of Beth Israel Deaconess Medical Center, affiliated with Harvard Medical School (protocol number #047-2-1226). All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals (Kilkenny *et al.*, 2010; McGrath *et al.*, 2010). A total of 35 animals were used in the experiments described here.

C57BL16 CB1-I knockout mice and WT littermate controls were bred from founders that were generously provided by Dr. Andreas Zimmer (Rheinische Evedeurich Wilhelms University, Bonn, Germany). Female mice at 5-8 weeks were used, as indicated. GFAP/Gp120 Tg mice and their control littermates (C57BL16X 129s strain) were kindly obtained from Dr. Eliezer Masliah's lab at the University of California, San Diego. Female mice at the age of 7 months were used, as indicated.

Treatment of GFAP/Gp120 Tg mice and control littermates with CB₂ receptor agonist AM1241

Control littermates and GFAP/Gp120 Tg mice (eight mice per group per treatment) were either treated with vehicle control or with the CB₂ receptor agonist, AM1241 at 10 mg·kg⁻¹. Mice received i.p. injection once a day continuously for 10 days, followed by 10 days of no treatment. After 10 days, these mice received again daily i.p. injection of AM1241 or vehicle control for another 10 days. Mice were then treated with bromodeoxyuridine (BrdU) for 5 days at 50 mg·kg⁻¹ and after 30 days, neurogenesis in the brain of these mice was analysed as described by Rockenstein *et al.*, 2007. A diagram of the dosing regimen is shown in Fig 5A.

Analysis of neurogenesis and apoptosis in vivo

Neurogenesis in the hippocampus of GFAP/Gp120 Tg mice and control mice was assessed as described previously (Rockenstein *et al.*, 2007). Briefly, mice were anesthetized with chloral hydrate and perfused transcardially with 0.9% saline. Brains were removed and divided sagittally. One hemisphere was snap frozen and stored at -70°C for protein analysis and the other fixed in 4% paraformaldehyde (pH 7.4) at 4°C for 48 h and sectioned with a Vibratome 2000 (Leica, Germany).

For detection of markers of neurogenesis, sagittal sections (see above) of mouse brain were incubated with antibodies against BrdU (marker of dividing cells; rat monoclonal, 1:100, Oxford Biotechnology, Oxford, UK), proliferating cell nuclear antigen (PCNA, marker of proliferation; mouse monoclonal, 1:250, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or doublecortin (DCX, marker of migrating neuroblasts; goat polyclonal, 1:500, Santa Cruz) overnight at 4°C. Sections were then incubated with biotinylated secondary antibodies directed against rat, mouse, or goat. After rinsing in Tris-buffered saline (TBS), avidin–biotin–peroxidase complex was applied (ABC Elite kit, Vector) followed by peroxidase detection with diaminobenzidine. For analysis of the proportion of BrdU⁺ cells converting into neurons or astroglial cells, double immunofluorescence labeling was performed with antibodies against BrdU and NeuN, and BrdU and GFAP. All sections

were processed under the same standardized conditions. The immunolabeled blind-coded sections were imaged with the LSCM (MRC1024, BioRad).

For detection of apoptosis in NPCs, the terminal deoxynucleotidyl transferase dUTP Nick End Labeling (TUNEL) detection method using the ApopTag *in situ* Apoptosis Detection Kit (Chemicon) was used with slight modifications. Detection was performed with Avidin-FITC and sections were mounted under glass coverslips with anti-fading media (Vector) for confocal microscopy analysis. To confirm that NPC undergo apoptosis, sections were double-labeled with a monoclonal antibody against activated caspase-3 (1:200, Stressgen Bioreagents, Ann Arbor, MI) and the polyclonal antibody against DCX (1:500, Santa Cruz), followed by incubation with Fluorochrome-labeled secondary antibodies and imaging on the LSCM.

Data analysis

All values are expressed as mean $\pm$ SEM. Analyses were carried out with the StatView 5.0 program (SAS Institute Inc., Cary, NC, USA). Differences among group means were assessed by one-way ANOVA with *post hoc* Dunnett's test (when comparing to the non-Tg control group) or the Tukey–Kramer test (when comparing between treatment groups). Means of two groups were compared with the two-tailed unpaired Student's *t*-test. Correlation studies were carried out by simple regression analysis and the null hypothesis was rejected at the 0.05 level.

Materials

HIV-1/Gp120 protein from HIV-1 strain III B recombinant protein, originally isolated from a CXCR4-preferring strain of HIV-1 (ImmunoDiagnostics Inc. Woburn, MA, USA), was used at an optimal concentration of 1 nM as reported earlier (Iskander *et al.*, 2004; Walsh *et al.*, 2004; Bunnik *et al.*, 2010). This is based on dose responses and kinetics studies performed in our lab (data not shown). In some experiments, we used Gp120 R5 strain (Ba-L) of HIV-1 (ImmunoDiagnostics, Inc.).

Anti-CB₁ and anti-CB₂ receptor antibodies (ABR-Affinity BioReagents, Golden, CO, USA) were used for immunostaining. Immunophenotyping of CB₂ receptors was confirmed by using another anti-CB₂ receptor antibody obtained from Sigma (St. Louis, MO, USA).

Arachidonyl-2'-chloroethylamide (ACEA), a selective agonist at CB₁ receptors, and the cannabinoid receptor antagonists AM251 (for CB₁) and AM630 (for CB₂) were purchased from Tocris Cookson (Ellisville, MO, USA). AM1241 is a CB₂ receptor agonist with a K_i value of 2 nM and greater than 100-fold selectivity over CB₁ receptors *in vitro*. The antinociceptive actions of AM1241 are blocked by the selective CB₂ receptor antagonist AM630 (Ibrahim *et al.*, 2003; 2005). AM630 with K_i = 31.2 nM displays 165-fold selectivity for CB₂ over CB₁ receptors (Tocris). URB597, an inhibitor of fatty acid amide hydrolase (FAAH) was obtained from Cayman Chemical (Cat #10046; Ann Arbor, Michigan). Another CB₂ receptor agonist JWH-015 was used at 10 μ M (Tocris Cookson). The CB₂ receptor agonist AM1241 was synthesized by Dr. A. Makriyannis.

Results

Expression of CB₁ and CB₂ receptors in human NPCs

First, we examined the expression of cannabinoid receptors in hNPCs. RT-PCR analysis (Figure 1A) and Western blot analysis (Figure 1B) showed hNPCs express both CB₁ and CB₂ receptors. The specificity of CB₁ and CB₂ antibodies was tested by Western blot and immunostaining analysis using cells positive for CB₁ receptors only (human SH-SY5Y; Figure 1C1) and cells positive for CB₂ receptors only (Jurkat T-cells; Figures 1 and 2). These results suggest that human NPCs express CB₁ and CB₂ receptors similar to murine NPCs. Therefore, we proposed that hNPCs might be responsive to the protective effects of cannabinoid receptor agonists in response to challenge with HIV-1/Gp120, as detailed below.

Effects of cannabinoid receptor agonists and HIV-1/Gp120 on human NPC proliferation

The CB₂ receptor agonist HU-308 is reported to stimulate NPCs (Palazuelos *et al.*, 2006). Thus, we examined the effects of another CB₂ receptor agonist AM1241 on hNPC proliferation, at various concentrations with or without HIV-1/Gp120. hNPCs were either untreated or treated with AM1241, with or without HIV-1/Gp120. After 7 days, the cells were fixed and immunostained with mouse anti-human Ki-67 PCNA expressed in the active stages of the cell cycle. The coverslips were counterstained with Hoechst 33342 to determine total cell numbers. As shown in Figure 2A, Gp120 inhibited hNPC proliferation and AM1241 prevented Gp120 from inhibiting hNPC proliferation. The optimal concentration was 1 nM for Gp120 based on our preliminary experiments and earlier

Figure 1

CB₁ and CB₂ receptor expression in human NPCs. (A) RNA from human NPC cells was extracted and then cDNA and PCR amplification were performed. CB₁ was amplified and yielded a product of 403 bp. CB₂ was amplified and yielded a product of 1100 bp. GAPDH was used as a positive control yielding a product of 292 bp. (B, C) Western blot analysis of CB₁ and CB₂ receptor expression. NPC cells were lysed and the lysates were separated by SDS-PAGE. Lysates of the SH-SY5Y human neuroblastoma cell line were used as a negative control for CB₂ receptor expression and as a positive control for CB₁ receptors.

Figure 2

Functional analysis of the effects of CB receptor agonists on human NPCs following exposure to HIV-1/Gp120. (A) Gp120 and AM1241 were used as indicated. hNPCs were grown in the presence of control vehicle; varying concentrations of Gp120 (as indicated); or Gp120 (1 nM) and varying concentrations of AM1241 (as indicated) for 48 h. The cells were monitored and analysed by microscopy after 48 h, using MTT assay. hNPC survival was increased on addition of AM1241 to the Gp120-treated cells. * $P < 0.05$, significant differences as indicated; $n = 3$. (B) Effects of Gp120 and CB receptor agonists on apoptosis of hNPC cells. Human NPCs (3×10^4) were cultured on eight-well chamber slides coated with laminin and maintained in ReNcell NSC Medium with freshly added FGF and EGF. Cells were treated as follows: untreated, with Gp120, with CB receptor ligands and/or Gp120 for 48 h as indicated. (C) Effects of AM1241 on Gp120-induced apoptosis. Apoptosis was detected using TUNEL assay after 48 h. Nuclei were stained with DAPI. Negative control included cells treated with proteinase K and positive control included cells digested with DNase I. For quantification of cell death by the TUNEL assay, approximately 50 hNPCs were analysed in each experiment. The proportion of TUNEL-positive cells was increased significantly on addition of AM1241 to the Gp120-treated cells. (D) Effects of AM1241 (100 nM) and the CB₁ receptor agonist ACEA (1 μ M) on apoptosis induced by Gp120 (1 nM). * $P < 0.05$, significant differences as indicated; $n = 3$.

reports Iskander *et al.*, 2004 and Bunnik *et al.*, 2010). The optimal concentration was 100 nM for AM1241 (Figure 2A). Similar effects on hNPCs were obtained with the CB₂ receptor agonist JWH-015 (data not shown). Thus, Gp120 (1 nM) decreased hNPC proliferation, and AM1241 inhibited Gp120-induced decrease proliferation of hNPCs. These studies (Figure 2A) are in agreement with reports that cannabinoids increased NPC proliferation *in vivo* (Aguado *et al.*, 2005).

Effects of HIV-1/Gp120 and cannabinoid receptor agonists on apoptosis of human NPCs

We then examined the effects of the CB₂ receptor agonist AM1241 on hNPC apoptosis, with or without treatment with HIV-1/Gp120. Detection of hNPC apoptosis was performed by TUNEL assay. Gp120 at 1 nM caused cell death (Figure 2B), which was inhibited by AM1241 optimally at 100 nM (Figure 2B, C). In addition, quantitative analysis of cell death by TUNEL assay revealed that AM1241 or the

selective CB₁ receptor agonist ACEA significantly reduced cell death mediated by Gp120 (Figure 2D), indicating the importance of endocannabinoids in protecting hNPCs (Figure 2D).

Effects of Gp120 and cannabinoid receptor agonists on human NPC differentiation

To examine the effects of cannabinoid receptor agonists on hNPC differentiation to neuronal cells, we employed the known marker MAP-2 (Maurin *et al.*, 2009). Gp120 induced significant cell death of hNPCs and few MAP-2-positive cells were detected in samples treated by Gp120 alone (Figure 3A,B). However, differentiation of hNPCs to neuronal cells in the presence of AM1241 (data not shown) or URB597 was observed (Figure 3A). Further, increase in MAP-2 staining was observed in hNPCs treated with Gp120+AM1241 or Gp120+URB597, compared with the staining in control hNPCs (Figure 3A). Quantitative analysis of the effects of AM1241 and URB597 on differentiation of hNPCs to neuronal cells is shown in Figure 3B.

Figure 3

Effects of Gp120 and CB receptor agonists on hNPC differentiation. (A) Immunostaining analysis of positive neuronal cells derived from hNPC. hNPCs (3×10^4) were cultured on an eight-well chamber slide, as described above. The cells were either treated or untreated with AM1241 (100 nM) or the FAAH inhibitor URB597, in the presence or absence of 1 nM of Gp120. The medium was replaced every 2 days and the cultures were kept for 2 weeks. Differentiation was detected by immunofluorescence staining using MAP-2 antibody, a marker for neuronal cells. Confocal microscopy analysis was performed (using a Zeiss LAM 510Meta). This is a representative experiment out of three experiments. (B) Quantification of neuronal cells derived from hNPCs, staining positive for MAP-2 antibody in the presence or absence of AM1241 or URB597. hNPCs were treated as indicated in Figure 3A. MAP-2-positive cells were determined with an optical fluorescence microscope analysing approximately 100 hNPCs from each experiment. * $P < 0.05$, significantly different from cells treated with Gp120 alone; $n = 3$.

The *in vivo* effect of cannabinoid receptor agonists on murine NPCs

To examine the effects of CB₂ receptor agonists on murine and hNPCs, we established conditions where mES cells can differentiate into NPCs. For this purpose, we first used the mES cell line E14/GFP cells, where GFP was tagged to mES cells (Figure 4A). These cells did not express CB₁ or CB₂ receptors (Figure 4B). However, NPCs derived from these mES cells showed CB₁ and CB₂ receptor expression by RT-PCR analysis and Western blot analysis (Figure 4C). The specificity of the CB₁ receptor antibody is shown by its reactivity to CB₁ receptors expressed in brain of WT mice but

not in brain from CB₁^{-/-} mice (see Figure 4D–E). NPCs isolated from adult mice showed similar pattern of CB₁ and CB₂ receptor expression as in NPCs derived from mES cells (data not shown). Functional assays showed that the CB₂ receptor agonist AM1241 inhibited Gp120-induced toxicity on murine NPCs. Specifically, AM1241 inhibited Gp120-induced apoptosis (Figure 4H). Further, AM1241 enhanced survival (Figure 4H) and increased differentiation of murine NPCs to neuronal cells (Figure 4I). These effects were mediated by CB₂ receptors as pretreatment of NPCs with the CB₂ receptor antagonist AM630 abolished these AM1241-mediated effects on survival and differentiation of NPCs (Figure 4H–I).

Figure 4

Expression of CB₁ and CB₂ receptors and functional analysis of neurogenesis in murine NPCs, derived from murine ES cells. (A) Differentiation of murine E14/GFP ES cells to EBs. (B) RT-PCR analysis of mES cells and neural progenitor cells derived from mES cells. Lane 1: murine ES cells; lane 2: neural progenitor cells derived from ES cells. (C) Western blot analysis of CB₁ and CB₂ in mES cells (lane 1) and neural progenitor cells derived from ES cells (lane 2). (D) Genotype screening and protein expression in CB₁ knockout and WT mice. The size of the cDNA fragments obtained by PCR for the WT mice was 1237 bp and 1088 bp for the CB₁ knockout mice. (E) Protein expression analysis by Western blot assay in brain total lysates derived from CB₁ knockout mice and WT mice. Brain tissues were obtained, lysed and analysed by Western blotting with specific antibodies against CB₁ receptors and tyrosine kinase C-terminal SRC kinase (CSK), as loading control. (F) Apoptosis: Gp120 was added to murine NPCs at 1 nM for 48 h. Apoptotic cell death was determined by TUNEL assay. (G) Proliferation: murine NPCs were exposed to Gp120 (1 nM) or Gp120 (R5) (1 nM) or Gp120-denatured at 100°C for 15 min (1 nM) or control solution. Cells were grown in media containing low concentration of EGF and FGF (1 ng·mL⁻¹). After 7 days, the cells were fixed and immunostained with ki67. In addition, coverslips were counterstained with Hoechst 33342 (2 mg·mL⁻¹) to determine total cell numbers. To assess the percentage of cell proliferation, the number of ki67-positive cells as well as the Hoechst-stained cells were counted for five fields each per coverslip. (H) Survival: quantitation of murine NPCs following exposure to Gp120 for 48 h, untreated or treated with AM1241 (100 nM) in the presence or absence of CB₂ receptor antagonist AM630 (1 mM). Percentages of survival of NPCs were analysed using MTT assay. (I) Quantification of positive neuronal cells derived from murine NPCs stained with MAP-2 antibody in the presence or absence of CB₂ receptor agonist AM1241 and CB₂ receptor antagonist AM630, as indicated. In all panels (A–I), the data are presented as mean ± SEM (*n* = 3). **P* < 0.05, significant differences as indicated.

The in vivo effect of AM1241 on neurogenesis in brains of GFAP/Gp120 transgenic mice

GFAP/Gp120 Tg mice display deficits in neurogenesis in the hippocampus (Okamoto *et al.*, 2007). To investigate if the alterations in neurogenesis in GFAP/Gp120 Tg can be reversed by CB₂ receptor agonists, 7-month old GFAP/Gp120 Tg mice and age-matched WT littermate control mice received AM1241 or vehicle control daily for 10 days, followed by 10 days of no treatment and again administered with vehicle control or AM1241 daily for 10 days (see protocol in Figure 5A). Next, a series of five BrdU injections were administered daily for 5 days and after 30 days (Figure 5A), the levels of markers of neurogenesis were analysed in the hippocampal subgranular zone (SGZ). As predicted, compared with the WT vehicle group, the GFAP/Gp120 Tg vehicle group displayed a reduction in the numbers of BrdU⁺ (Figure 5B, a–b), doublecortin positive (DCX⁺; Figure 5B, c–d) and PCNA⁺ (Figure 5B, e–f) cells in the SGZ. Moreover, double labelling studies with antibodies against BrdU, NeuN and GFAP showed a decrease in neuroblasts converting to neurons (Figure 6A,B) and an increase in neural precursors converting to astroglial cells (Figure 6C,D) in the brain of GFAP/Gp120 Tg vehicle group, compared with control mice treated with vehicle. In contrast, analysis of the SGZ of the GFAP/Gp120 Tg mice treated with AM1241, compared with GFAP/Gp120 Tg mice treated with vehicle, showed an increase in BrdU⁺ cells (Figure 5B, panels a,b); DCX⁺ cells (Figure 5B, panels c,d); and PCNA⁺ cells (Figure 5B, panels e,f). In addition, decreased numbers of GFAP-positive cells (Figure 6C,D) were observed in GFAP/Gp120 Tg mice treated with AM1241, compared with those in GFAP/Gp120 Tg mice treated with vehicle only. Thus, treatment with the CB₂ receptor agonist AM1241 prevented deficits in neurogenesis observed in GFAP/Gp120 Tg mice.

Discussion

This study focused on understanding the inhibitory effects of Gp120 on neurogenesis both *in vitro* and *in vivo* and the protective effects of CB₂ receptor agonists on this process. Using *in vitro* cultures of human and murine NPCs, we showed that two agonists for CB₂ receptors, JWH-015 and AM1241, inhibited Gp120-mediated toxicity in both murine (Figure 4) and human NPCs (Figures 1–3). AM1241 also promoted the differentiation of human and murine NPCs into neuronal cells (Figures 3 and 4I). Further, our *in vivo* data showed that administration of AM1241 significantly improved neurogenesis in GFAP/Gp120 Tg mice and decreased astrogliosis and gliogenesis (Figures 5 and 6; anti-inflammatory effects).

Several studies have confirmed the toxic effects of Gp120 on the neuronal population (Bari *et al.*, 2010). Neonatal rats treated systemically with Gp120 showed retardation in behavioral development (Corasaniti *et al.*, 2001). Gp120 induced apoptosis in the brain neocortex of adult rats treated with a dose of 100 ng of viral protein for 7 consecutive days (Corasaniti *et al.*, 2001). Bilateral injection of Gp120 (10–100 nM) into the intermediate medial mesopallium of

chicken forebrain caused amnesia (Corasaniti *et al.*, 2001). Some studies show that Gp120 impairs memory retention in rodents (Corasaniti *et al.*, 2001). The ability of macrophages to produce pro-inflammatory cytokines like TNF- α and IL-1 may further increase neuronal cell death (Wyss-Coray *et al.*, 1996; Corasaniti *et al.*, 2001). In addition, HIV-1/Gp120, by activating FAAH and inducing neuronal apoptosis, enhanced AEA degradation (Maccarrone *et al.*, 2004).

The ability to isolate and differentiate CNS progenitor cells in culture allows studies to focus on functional and neurodevelopmental consequences of progenitor cell infection in the brain following exposure to HIV-1-derived toxins (such as Gp120). HIV-1/Gp120 is a potent neurotoxin in NPCs in which its effects are mediated through its interaction with the chemokine receptor CXCR4 expressed on hNPCs (Tran *et al.*, 2005). Using human NPCs, we were able to show that HIV-1/Gp120 inhibits proliferation optimally at concentration of 1 nM (Figure 2A) and induces apoptosis of in these cells (Figure 2B). The endocannabinoid system exerts an important neuromodulatory role in different types of synapses (Galve-Roperh *et al.*, 2009) and is involved in the regulating the fate of of neural cells. There is an orchestrated pattern of CB₁ receptor expression, endocannabinoid production and appearance of endocannabinoid-metabolizing enzymes during cortical development (Galve-Roperh *et al.*, 2009). In this regard, it is important to note that the selective CB₁ receptor agonist ACEA was also neuroprotective and inhibited Gp120-induced damage of NPCs *in vitro* (Figure 2D). Further, we demonstrated neuroprotective effect of the CB₂ receptor agonist AM1241 on neurogenesis in GFAP/Gp120 Tg mice *in vivo* (Figure 5). These mice display deficits in neurogenesis in the hippocampus. However, after administration of AM1241 to these mice, enhanced *in vivo* neurogenesis was observed as indicated by a significant increase in the number of neuroblasts and neuronal cells, increase in the number of BrdU⁺ cells and DCX⁺ cells as well as an increase in the number of PCNA⁺ cells (Figure 5B), and a significant decrease in astrogliosis and gliogenesis (Figure 6). These results demonstrate that AM1241 reversed the impaired neurogenesis caused by HIV-1/Gp120. The one possible mechanism underlying the protective effects of AM1241 on neurogenesis might be via modulating inflammatory pathways, as demonstrated by decrease in astrogliosis and gliogenesis (Figure 6). Indeed, endocannabinoids protect neurons during CNS inflammation induced by MKP-1 microglial cells (Eljaschewitsch *et al.*, 2006).

The proliferating cells in the adult mouse subventricular zone (SVZ) express DAG lipases (DAGLs), enzymes that synthesize the endocannabinoid agonist ligands (Goncalves *et al.*, 2008). While both DAGL and CB₂ receptor antagonists inhibited the proliferation of cultured neural stem cells and the proliferation of progenitor cells in young animals, CB₂ receptor agonists stimulated progenitor cell proliferation *in vivo* (Goncalves *et al.*, 2008). Earlier studies showed that CB₂ receptor agonists stimulated NPC proliferation as analysed in NPC cultures and in CB₂^{-/-} mice using positive BrdU⁺ cells (Palazuelos *et al.*, 2006). Agonists at CB₂ receptors promoted NPC proliferation via mTORC1 signalling (Palazuelos *et al.*, 2012). However, these studies lack the detailed analysis of the *in vivo* neurogenesis in these mice, and therefore, it is not

Figure 5

Effects of AM1241 on neurogenesis *in vivo*. (A) GFAP/Gp120 Tg mice and their WT littermate control were either treated with vehicle control or with AM1241 (10 mg·kg⁻¹) for the first 10 days. No treatment was given for the following 10 days. Then, AM1241 or vehicle control was administered daily for the following 10 days. All mice then received BrdU (50 mg·kg⁻¹) by injection for 5 days, and the experiments were terminated after 30 days and brains were analysed for neurogenesis. (B) Analysis of neurogenesis in GFAP/Gp120 transgenic mice and WT mice, treated with AM1241. (a–b) Immunohistological analysis of BrdU⁺ cells and quantitative analysis in the SGZ of BrdU⁺ cells in GFAP/Gp120 Tg mice treated with AM1241. **P* < 0.001, significantly different from WT mice treated with AM1241; Student's *t*-test; *n* = 8 per group. (c–d) Immunocytochemical analysis of DCX⁺ and quantitative analysis of DCX⁺ cells using the disector method in the SGZ shows increased numbers of DCX⁺ neurons in GFAP/Gp120 Tg mice after AM1241 treatment, compared with vehicle control treatment. **P* < 0.001. GFAP/Gp120 Tg with vehicle significantly different from WT mice with vehicle control; ***P* < 0.001, GFAP/Gp120 Tg with AM1241 significantly different from GFAP/Gp120 treated with vehicle; one-way ANOVA with *post hoc* Dunnett's test; *n* = 8. (e–f) Immunocytochemical analysis of PCNA⁺ cells in GFAP/Gp120 Tg and WT mice treated with vehicle or AM1241. Quantitative analysis using the disector method in the SGZ showing the numbers of PCNA⁺ NPC cells. **P* < 0.001, GFAP/Gp120 Tg treated with AM1241 significantly different from vehicle; one-way ANOVA with *post hoc* Dunnett's test; (*n* = 8).

Figure 6

Effects of *in vivo* administration of AM1241 on NeuN⁺ cells and astroglial cells. (A–B) Immunohistological analysis of NeuN⁺ cells within the BrdU⁺ cell population and estimates of the numbers of NeuN⁺ neurons within the BrdU⁺ cells in the hippocampal dentate gyrus using the disector method. * $P < 0.005$, significant differences as indicated; one-way ANOVA with *post hoc* Tukey Kramer test; $n = 8$. (C–D) Immunostaining and analysis of NPCs converting to astroglial cells. Conversion of NPCs to astroglial cells (GFAP immunoreactivity) within the BrdU⁺ cells in the hippocampal dentate gyrus. * $P < 0.001$, significant differences as indicated; one-way ANOVA with *post hoc* Tukey Kramer test; $n = 8$.

clear whether CB₂ receptor-mediated cell proliferation is absent in basal conditions *in vivo*, as indicated by our studies.

CB₂ receptor agonists decreased chronic neuroinflammation and restored hippocampal neurogenesis and improved memory in aged rats (Marchalant *et al.*, 2008; 2009a,b,c; 2012). The endocannabinoids may regulate many aspects of the brain's inflammatory response, including the release of pro-inflammatory cytokines and modulation of astrocytic and microglial activation. In addition to the CB₂ receptor-mediated effects on neurogenesis, it is important to note that we also observed significantly decreased astroglial and gliogenesis in GFAP/Gp120 Tg mice following the administration of AM1241. Thus, AM1241 enhanced neurogenesis and attenuated the neuroinflammation induced by Gp120 in GFAP/Gp120 Tg mice.

Based on the results presented in this study focusing on CB₂ receptor-mediated effects, we propose that selective agonists at the CB₂ receptor may protect NPCs from the neurotoxic effects of HIV-1 proteins such as Gp120 and may therefore represent a potentially promising neuroprotective treatment for patients with HIV-1-associated neurocognitive disorders. A new opportunity for the development of cannabinoid-based analgesics emerged from data showing that selective CB₂ receptor agonists are anti-nociceptive in animal pain models, suggesting that neural cells are involved in pain perception and/or modulation through CB₂ receptors (Marsicano *et al.*, 2003; Ramírez *et al.*, 2005; Sarne and Mechoulam, 2005; Galve-Roperh *et al.*, 2006; 2008; 2009; Panikashvili *et al.*, 2006; Katona and Freund, 2008; Heifets and Castillo, 2009). We have shown here that NPCs expressed CB₂ receptors abundantly and that the CB₂ receptor agonist

AM1241 exerted neuroprotective effects on NPCs after insult by Gp120.

In summary, these findings support the hypothesis that CB₂ receptor agonists have neuroprotective effects on impaired neurogenesis induced by HIV-1/Gp120 in GFAP/Gp120 Tg mice.

Acknowledgements

This work was funded by the Department of Experimental Medicine at Beth Israel Deaconess Medical Center. We thank Esther Lee, Lili Wang and Benjamin Chen for their help and support in the typing, proofreading and editing of the manuscript.

Conflicts of interest

There exist no conflicts of interest.

References

- Aguado T, Monory K, Palazuelos J, Stella N, Cravatt B, Lutz B *et al.* (2005). The endocannabinoid system drives neural progenitor proliferation. *FASEB J* 19: 1704–1706.
- Albright AV, Martin J, O'Connor M, Gonzalez-Scarano F (2001). Interactions between HIV-1 gp120, chemokines, and cultured adult microglial cells. *J Neurovirol* 7: 196–207.
- Alexander SPH *et al.* (2013). The Concise Guide to PHARMACOLOGY 2013/14: Overview. *Br J Pharmacol* 170: 1449–1867.
- Bari M, Rapino C, Mozetic P, Maccarrone M (2010). The endocannabinoid system in gp120-mediated insults and HIV-associated dementia. *Exp Neurol* 224: 74–78.
- Bunnik EM, Euler Z, Welkers MR, Boeser-Nunnink BD, Grijsen ML, Prins JM *et al.* (2010). Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. *Nat Med* 16: 995–997.
- Cherner M, Ellis RJ, Lazzaretto D, Young C, Mindt MR, Atkinson JH *et al.* (2004). Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. *AIDS* 18 (Suppl 1): S27–S34.
- Corasaniti MT, Maccarrone M, Nistico R, Malorni W, Rotiroti D, Bagetta G (2001). Exploitation of the HIV-1 coated glycoprotein, gp120, in neurodegenerative Studies in vivo. *J Neurochem* 79: 1–8.
- Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S *et al.* (2006). The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. *Neuron* 49: 67–79.
- Fauci AS (1988). The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. *Science* 239: 617–622.
- Galve-Roperh I, Aguado T, Rueda D, Velasco G, Guzmán M (2006). Endocannabinoids: a new family of lipid mediators involved in the regulation of neural cell development. *Curr Pharm* 12: 2319–2325.
- Galve-Roperh I, Aguado T, Palazuelos J, Guzmán M (2008). Mechanisms of control of neuron survival by the endocannabinoid system. *Curr Pharm* 14: 2279–2288.
- Galve-Roperh I, Palazuelos J, Aguado T, Guzmán M (2009). The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders. *Eur Arch Psychiatry Clin Neurosci* 259: 371–382.
- Goncalves MB, Suetterlin P, Yip P, Molina-Holgado F, Walker DJ, Oudin MJ *et al.* (2008). A diacylglycerol lipase-CB₂ cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner. *Mol Cell Neurosci* 38: 526–536.
- Heifets BD, Castillo PE (2009). Endocannabinoid signaling and long-term synaptic plasticity. *Annu Rev Physiol* 71: 283–306.
- Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP *et al.* (2003). Activation of CB₂ cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. *PNAS* 100: 10529–10533.
- Ibrahim MM, Porreca F, Lai J, Albrecht P, Rice FL, Khodorova A *et al.* (2005). CB₂ cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. *PNAS* 102: 3093–3098.
- Iskander S, Walsh KA, Hammond RR (2004). Human CNS cultures exposed to HIV-1 gp120 reproduce dendritic injuries of HIV-1-associated dementia. *J Neuroinflammation* 1: 1–9.
- Katona I, Freund TF (2008). Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. *Nat Med* 14: 923–930.
- Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: Reporting *in vivo* experiments: The ARRIVE guidelines. *Br J Pharmacol* 160: 1577–1579.
- Kim HJ, Shin AH, Thayer SA (2011). Activation of CB₂ cannabinoid receptors inhibits HIV-1 envelope glycoprotein Gp120-induced synapse loss. *Mol Pharmacol* 80: 357–366.
- Krucker T, Toggas SM, Mucke L, Siggins GR (1998). Transgenic mice with cerebral expression of human immunodeficiency virus type-1 coat protein gp120 show divergent changes in short- and long-term potentiation in CA1 hippocampus. *Neuroscience* 83: 691–700.
- Louboutin JP, Strayer DS (2012). Blood-brain barrier abnormalities caused by HIV-1/Gp120: mechanistic and therapeutic implications. *Sci World J* 2012: 482575.
- McArthur JC, Steiner J, Sacktor N, Nath A (2010). Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. *Ann Neurol* 67: 699–714.
- Maccarrone M, Piccirilli S, Battista N, Del Duca C, Nappi G, Corasaniti MT *et al.* (2004). Enhanced anandamide degradation is associated with neuronal apoptosis induced by the HIV-1 coat glycoprotein gp120 in the rat neocortex. *J Neurochem* 89: 1293–1300.
- Marchalant Y, Cerbai F, Brothers HM, Wenk GL (2008). Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats. *Neurobiol Aging* 29: 1894–1901.
- Marchalant Y, Brother HM, Norman GJ, Karelina K, DeVries AC, Wenk GL (2009a). Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis. *Neurobiol Dis* 34: 300–307.
- Marchalant Y, Brothers HM, Wenk GL (2009b). Cannabinoid agonist WIN-55, 212-2 partially restores neurogenesis in the aged rat brain. *Mol Psychiatry* 14: 1068–1069.
- Marchalant Y, Brothers HM, Wenk GL (2009c). New neuron production can be increased in the hippocampus of aged rats following cannabinoid treatment. *Mol Psychiatry* 14: 1067.

- Marchalant Y, Baranger K, Wenk GL, Khrestchatisky M, Rivera S (2012). Can the benefits of cannabinoid receptor stimulation on neuroinflammation, neurogenesis and memory during normal aging be useful in AD prevention. *J Neuroinflammation* 9: 10.
- Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A *et al.* (2003). CB₁ cannabinoid receptors and on demand defense against excitotoxicity. *Science* 302: 84–88.
- Mattson MP, Haughey NJ, Nath A (2005). Cell death in HIV dementia. *Cell Death Differ* 12: 893–904.
- Maurin JC, Couble ML, Staquet MJ, Carrouel F, About I, Avila J *et al.* (2009). Microtubule-associated protein 1b, a neuronal marker involved in odontoblast differentiation. *J Endod* 35: 992–996.
- McGrath J, Drummond G, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. *Br J Pharmacol* 160: 1573–1576.
- Mucke L, Abraham CR, Ruppe MD, Rockenstein EM, Toggas SM, Mallory M *et al.* (1995). Protection against HIV-1/Gp120-induced brain damage by neuronal expression of human amyloid precursor protein. *J Exp Med* 181: 1551–1556.
- Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K *et al.* (1999). Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. *J Neurosci* 19: 2987–2995.
- Okamoto S, Kang YJ, Brechtel CW, Siviglia E, Russo R, Clemente A *et al.* (2007). HIV/gp120 decreases adult neural progenitor cell proliferation via checkpoint Kinase-Mediated Cell-Cycle withdrawal and G1 arrest. *Cell Stem Cell* 1: 230–236.
- Palazuelos J, Aguado T, Egia A, Mechoulam R, Guzmán M, Galve-Roperh I (2006). Non-psychoactive CB₂ cannabinoid agonists stimulate neural progenitor proliferation. *FASEB J* 20: 2405–2407.
- Palazuelos J, Ortega Z, Díaz-Alonso J, Guzmán N, Galve-Roperh I (2012). CB₂ cannabinoid receptors promote neural progenitor cell proliferation via mTORC1 signalling. *J Biol Chem* 287: 1198–1209.
- Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A *et al.* (2006). The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. *Neurobiol Dis* 22: 257–264.
- Price RW, Spudich S (2008). Antiretroviral therapy and central nervous system HIV type 1 infection. *J Infect Dis* 197 (Suppl 3): S294–S306.
- Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML (2005). Prevention of Alzheimer's disease by cannabinoids: neuroprotection mediated by blockade of microglial activation. *J Neurosci* 25: 1904–1913.
- Rockenstein E, Mante M, Adame A, Crews L, Moessler H, Masliah E (2007). Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease. *Acta Neuropathol* 113: 265–275.
- Sarne Y, Mechoulam R (2005). Cannabinoids: between neuroprotection and neurotoxicity. *Curr Drug Targets CNS Neurol Disord* 4: 677–684.
- Scott JC, Woods SP, Carey CL, Weber E, Bondi MW, Grant I (2011). HIV Neurobehavioral Research Center (HNRC) Group: neurocognitive consequences of HIV infection in older adults: an evaluation of the 'cortical' hypothesis. *AIDS and Behav* 15: 1187–1196.
- Shah A, Kumar A (2010). HIV-1/Gp120-mediated increases in IL-8 production in astrocytes are mediated through the NF-κB pathway and can be silenced by gp120-specific siRNA. *J Neuroinflammation* 29: 96.
- van der Stelt M, Veldhuis WB, Bär PR, Veldink GA, Vliegenthart JF, Nicolay K (2001). Neuroprotection by Δ⁹-tetrahydrocannabinol, the main active compound of marijuana, against ouabain-induced in vivo excitotoxicity. *J Neurosci* 21: 6475–6479.
- Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L (1994). Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. *Nature* 367: 188–193.
- Toggas SM, Masliah E, Mucke L (1996). Prevention of HIV-1/Gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine. *Brain Res* 706: 303–307.
- Tran PB, Ren D, Miller RJ (2005). The HIV-1 coat protein gp120 regulates CXCR4-mediated signaling in neural progenitor cells. *J Neuroimmunol* 160: 68–76.
- Walsh KA, Megyesi JF, Wilson JX, Crukley J, Laubach VE, Hammond RR (2004). Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity. *J Neuroinflammation* 1: 8.
- Wiley CA, Achim CL, Christopherson C, Kidane Y, Kwok S, Masliah E *et al.* (1999). HIV mediates a productive infection of the brain. *AIDS* 13: 2055–2059.
- Wyss-Coray T, Masliah E, Toggas SM, Rockenstein EM, Brooker MJ, Lee HS *et al.* (1996). Dysregulation of signal transduction pathways as a potential mechanism of nervous system alterations in HIV-1/Gp120 transgenic mice and humans with HIV-1 encephalitis. *J Clin Invest* 97: 789–798.